1. Home
  2. RCEL vs SPXX Comparison

RCEL vs SPXX Comparison

Compare RCEL & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • SPXX
  • Stock Information
  • Founded
  • RCEL 2020
  • SPXX 2004
  • Country
  • RCEL United States
  • SPXX United States
  • Employees
  • RCEL N/A
  • SPXX N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • SPXX Trusts Except Educational Religious and Charitable
  • Sector
  • RCEL Health Care
  • SPXX Finance
  • Exchange
  • RCEL Nasdaq
  • SPXX Nasdaq
  • Market Cap
  • RCEL 274.7M
  • SPXX 302.8M
  • IPO Year
  • RCEL N/A
  • SPXX N/A
  • Fundamental
  • Price
  • RCEL $11.95
  • SPXX $17.35
  • Analyst Decision
  • RCEL Hold
  • SPXX
  • Analyst Count
  • RCEL 3
  • SPXX 0
  • Target Price
  • RCEL $16.50
  • SPXX N/A
  • AVG Volume (30 Days)
  • RCEL 75.6K
  • SPXX 51.3K
  • Earning Date
  • RCEL 11-07-2024
  • SPXX 01-01-0001
  • Dividend Yield
  • RCEL N/A
  • SPXX 7.55%
  • EPS Growth
  • RCEL N/A
  • SPXX N/A
  • EPS
  • RCEL N/A
  • SPXX N/A
  • Revenue
  • RCEL $60,040,000.00
  • SPXX N/A
  • Revenue This Year
  • RCEL $40.31
  • SPXX N/A
  • Revenue Next Year
  • RCEL $45.42
  • SPXX N/A
  • P/E Ratio
  • RCEL N/A
  • SPXX N/A
  • Revenue Growth
  • RCEL 32.24
  • SPXX N/A
  • 52 Week Low
  • RCEL $7.51
  • SPXX $13.57
  • 52 Week High
  • RCEL $18.93
  • SPXX $16.05
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 65.36
  • SPXX 71.34
  • Support Level
  • RCEL $10.05
  • SPXX $16.57
  • Resistance Level
  • RCEL $12.64
  • SPXX $16.96
  • Average True Range (ATR)
  • RCEL 0.58
  • SPXX 0.17
  • MACD
  • RCEL 0.19
  • SPXX 0.04
  • Stochastic Oscillator
  • RCEL 74.06
  • SPXX 100.00

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About SPXX Nuveen S&P 500 Dynamic Overwrite Fund

Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.

Share on Social Networks: